Update: Peripheral T-cell lymphomas

Current Hematologic Malignancy Reports

Volumn 6, Issue 4, 2011, Pages 222-230

  Savage, Kerry J ^a  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

AITL; ALCL; Anaplastic large cell lymphoma; Angioimmunoblastic T cell lymphoma; Gene expression profiling; Genetics; Novel therapies; Pathology; Peripheral T cell lymphoma; Prognosis; PTCL; PTCL NOS; Transplantation; Treatment

Indexed keywords

ALEMTUZUMAB; ANAPLASTIC LYMPHOMA KINASE; ANTHRACYCLINE; ASPARAGINASE; BLEOMYCIN; BORTEZOMIB; BRENTUXIMAB VEDOTIN; CISPLATIN; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DENILEUKIN DIFTITOX; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLIC ACID; GEMCITABINE; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; METHYLPREDNISOLONE SODIUM SUCCINATE; NUCLEOPHOSMIN; OXALIPLATIN; PRALATREXATE; PREDNISONE; RITUXIMAB; ROMIDEPSIN; VINBLASTINE; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; ANOREXIA; CANCER RELAPSE; CLINICAL TRIAL (TOPIC); COMPARATIVE GENOMIC HYBRIDIZATION; CONSTIPATION; DIARRHEA; DNA SEQUENCE; DRUG FATALITY; FATIGUE; FEBRILE NEUTROPENIA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENE MUTATION; HEMOLYTIC ANEMIA; HUMAN; HYPERGAMMAGLOBULINEMIA; KARYOTYPING; LARGE CELL LYMPHOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATHOLOGY; PERIPHERAL NEUROPATHY; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGNOSIS; RASH; REVIEW; SPLENOMEGALY; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; GENE EXPRESSION PROFILING; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; PREDNISONE; PROGNOSIS; STEM CELL TRANSPLANTATION; VINCRISTINE;

EID: 81355160508     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-011-0100-3     Document Type: Review

References (60)

1. N Harris E Jaffe H Stein, et al. 1994 A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group Blood 84 5 1361 92 8068936 1:STN:280:DyaK2czkvVSmtQ%3D%3D (Pubitemid 24273002)
2. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2008.
3. International T-Cell Lymphoma Project 2008 International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes J Clin Oncol 26 25 4124 30 10.1200/JCO.2008.16.4558
4. J Dupuis J Emile N Mounier, et al. 2006 Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study Blood 108 4163 4169 16902151 10.1182/blood-2006-04-017632 1:CAS:528:DC%2BD28XhtlWqsrjI (Pubitemid 44913288)
5. DD Weisenburger KJ Savage NL Harris, et al. 2011 Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project Blood 117 12 3402 8 21270441 10.1182/blood-2010-09-310342 1:CAS:528:DC%2BC3MXkslamsLs%3D This evaluation of prognostic factors in PTCL-NOS comes from the International Peripheral T-Cell Lymphoma Project
6. A Zettl T Rudiger MA Konrad, et al. 2004 Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations Am J Pathol 164 5 1837 48 15111330 10.1016/S0002-9440(10)63742-X 1:CAS:528:DC%2BD2cXns1Kjsrs%3D (Pubitemid 38529786)
7. C Thorns B Bastian D Pinkel, et al. 2007 Chromosomal aberrations in angioimmunoblastic T-cell lymphoma and peripheral T-cell lymphoma unspecified: a matrix-based CGH approach Genes Chromosom Cancer 46 1 37 44 17044049 10.1002/gcc.20386 1:CAS:528:DC%2BD28Xht1GntrnN (Pubitemid 44772870)
8. L de Leval P Gaulard 2011 Pathology and biology of peripheral T-cell lymphomas Histopathology 58 1 49 68 21261683 10.1111/j.1365-2559.2010.03704.x
9. B Ballester C Gisselbrecht P Gaulard, et al. 2005 Gene expression profiling identifies molecular subgroups among nodal peripheral T-cell lymphomas Ann Oncol 16 Supp 5 124a
10. J Iqbal DD Weisenburger TC Greiner, et al. 2010 Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma Blood 115 5 1026 36 19965671 10.1182/blood-2009-06-227579 1:CAS:528:DC%2BC3cXhvFOit70%3D This gene expression profiling study with a focus on AILT identifies molecular signatures associated with a favorable or unfavorable prognosis
11. L de Leval DS Rickman C Thielen, et al. 2007 The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells Blood 109 11 4952 63 17284527 10.1182/blood-2006-10-055145 (Pubitemid 46827794)
12. KJ Savage M Chhanabhai RD Gascoyne, et al. 2004 Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification Ann Oncol 15 10 1467 75 15367405 10.1093/annonc/mdh392 1:STN:280:DC%2BD2cvlvVGqtw%3D%3D (Pubitemid 39409735)
13. A Gallamini C Stelitano R Calvi, et al. 2004 Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood 103 7 2474 9 14645001 10.1182/blood-2003-09-3080 1:CAS:528:DC%2BD2cXjtValu70%3D (Pubitemid 38392996)
14. N Mourad N Mounier J Briere, et al. 2008 Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials Blood 111 9 4463 70 18292286 10.1182/blood-2007-08-105759 1:CAS:528: DC%2BD1cXlsVSku7o%3D
15. SW Morris MN Kirstein MB Valentine, et al. 1994 Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 1994 1281 4 10.1126/science.8122112 (Pubitemid 24107549)
16. D Mason C Bastard R Rimokh, et al. 1990 CD30-positive large cell lymphomas ("Ki-1 lymphoma") are associated with a chromosomal translocation involving 5q35 Br J Haematol 74 161 8 2156548 10.1111/j.1365-2141. 1990.tb02560.x 1:STN:280:DyaK3c7pvVymtw%3D%3D (Pubitemid 20041090)
17. L Lamant A de Reynies MM Duplantier, et al. 2007 Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes Blood 109 5 2156 64 17077326 10.1182/blood-2006-06-028969 1:CAS:528:DC%2BD2sXjtFequ7o%3D (Pubitemid 46348218)
18. O Merkel F Hamacher D Laimer, et al. 2010 Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma Proc Natl Acad Sci USA 107 37 16228 33 20805506 10.1073/pnas.1009719107 1:CAS:528:DC%2BC3cXhtF2htLbI
19. D Sibon M Fournier J Briere, et al. 2010 Prognostic factors and long term outcome of 138 adults with systemic anaplastic large-cell lymphoma: a retrospective study by the Groupe d'Etude Des Lymphomes De l'Adulte (GELA) Blood (ASH Annual Meeting Abstracts) 116 21 322 This large study of ALCL patients identified the importance of age as well as ALK status for prognosis
20. I Bonzheim E Geissinger S Roth, et al. 2004 Anaplastic large cell lymphomas lack the expression of T-cell receptor molecules or molecules of proximal T-cell receptor signaling Blood 104 10 3358 60 15297316 10.1182/blood-2004-03-1037 1:CAS:528:DC%2BD2cXhtVWhurvE (Pubitemid 39507158)
21. I Salaverria S Bea A Lopez-Guillermo, et al. 2008 Genomic profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell lymphomas Br J Haematol 140 5 516 26 18275429 10.1111/j.1365-2141.2007.06924.x (Pubitemid 351230071)
22. AL Feldman A Dogan DI Smith, et al. 2011 Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing Blood 117 3 915 9 21030553 10.1182/blood-2010-08-303305 1:CAS:528:DC%2BC3MXhslKksL4%3D This article reports on a novel technique to discover recurrent translocation in ALK-negative ALCL
23. DA Wada ME Law ED Hsi, et al. 2011 Specificity of IRF4 translocations for primary cutaneous anaplastic large cell lymphoma: a multicenter study of 204 skin biopsies Mod Pathol 24 4 596 605 21169992 10.1038/modpathol.2010.225 1:CAS:528:DC%2BC3MXktFGjtLw%3D
24. RL ten Berge PC de Bruin JJ Oudejans, et al. 2003 ALK-negative anaplastic large-cell lymphoma demonstrates similar poor prognosis to peripheral T-cell lymphoma, unspecified Histopathology 43 5 462 9 14636272 10.1046/j.1365-2559. 2003.01726.x (Pubitemid 37445237)
25. R Suzuki Y Kagami K Takeuchi, et al. 2000 Prognostic significance of CD56 expression for ALK-positive and ALK- negative anaplastic large-cell lymphoma of T/null cell phenotype Blood 96 9 2993 3000 11049976 1:CAS:528: DC%2BD3cXnslGnsbY%3D
26. R Gascoyne P Aoun D Wu, et al. 1999 Prognostic significance of anaplastic lymphoma kinase (ALK) protein expression in adults with anaplastic large cell lymphoma Blood 93 3913 21 10339500 1:CAS:528:DyaK1MXjsVOnt7o%3D (Pubitemid 29249840)
27. KJ Savage NL Harris JM Vose, et al. 2008 ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project Blood 111 12 5496 504 18385450 10.1182/blood-2008-01-134270 1:CAS:528:DC%2BD1cXnsVOkt7w%3D This is a detailed study from the International Peripheral T-Cell Lymphoma Project regarding ALCL
28. L Popplewell SH Thomas Q Huang, et al. 2011 Primary anaplastic large-cell lymphoma associated with breast implants Leuk Lymphoma 52 8 1481 7 21699454 10.3109/10428194.2011.574755
29. Lazzeri D, Agostini T, Bocci G, et al. ALK-1-negative anaplastic large cell lymphoma associated with breast implants: a new clinical entity. Clin Breast Cancer. 2011 May 11 (Epub ahead of print).
30. Kim B, Roth C, Young VL, et al. Anaplastic large cell lymphoma and breast implants: results from a structured expert consultation process. Plast Reconstr Surg. 2011 May 12 (Epub ahead of print).
31. RI Fisher ER Gaynor S Dahlberg, et al. 1993 Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma N Engl J Med 328 14 1002 6 7680764 10.1056/ NEJM199304083281404 1:STN:280:DyaK3s7ps1Kmtg%3D%3D (Pubitemid 23095683)
32. L Jiang CM Yuan J Hubacheck, et al. 2009 Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy Br J Haematol 145 2 173 9 19236377 10.1111/j.1365-2141.2009.07606.x 1:CAS:528:DC%2BD1MXltlSmsbs%3D
33. A Simon M Peoch P Casassus, et al. 2010 Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95 Br J Haematol 151 2 159 66 20738307 10.1111/j.1365-2141.2010.08329.x
34. N Schmitz L Trümper M Ziepert, et al. 2010 Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group Blood 116 18 3418 25 20660290 10.1182/blood-2010-02-270785 1:CAS:528:DC%2BC3cXhsVKksLfP This is a retrospective analysis of prospective studies evaluating the impact of etoposide on the outcome of PTCL
35. HC Kluin-Nelemans M van Marwijk Kooy PJ Lugtenburg, et al. 2011 Intensified alemtuzumab-CHOP therapy for peripheral T-cell lymphoma Ann Oncol 22 7 1595 600 21212158 10.1093/annonc/mdq635 1:STN:280:DC%2BC3Mnjt1aqsQ%3D%3D
36. JG Kim SK Sohn YS Chae, et al. 2007 Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study Cancer Chemother Pharmacol 60 1 129 34 17406867 10.1007/s00280-007-0469-9 1:CAS:528:DC%2BD2sXksVOgs70%3D (Pubitemid 46643727)
37. FM Foss A Sjak-Shie A Goy, et al. 2010 Phase II study of denileukin diftitox with CHOP chemotherapy in newly diagnosed PTCL: CONCEPT trial J Clin Oncol 28 15s 8045a
38. G Corazzelli F Frigeri G Marcacci, et al. 2010 Gemcitabine, Ifosfamide, Oxaliplatin (GIFOX) as first-line treatment in high-risk peripheral T-Cell/NK lymphomas: a phase II trial Blood (ASH Annual Meeting Abstracts) 116 21 2829
39. D Mahadevan JM Unger DO Persky, et al. 2011 Phase II trial of Cisplatin plus Etoposide plus Gemcitabine plus Solumedrol (PEGS) in peripheral T-cell non-Hodgkin lymphoma (SWOG S0350) Ann Oncol 22 Suppl 4 111a 5 282
40. A Jaccard N Gachard B Marin, et al. 2011 Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study Blood 117 6 1834 9 21123825 10.1182/blood-2010-09-307454 1:CAS:528:DC%2BC3MXisFKqs7s%3D This is a report of a promising new L-asparaginase combination for extranodal NK/T-cell lymphoma
41. MP Escalon NS Liu Y Yang, et al. 2005 Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma Cancer 103 10 2091 8 15816054 10.1002/cncr.20999 (Pubitemid 40605117)
42. F d'Amore T Relander GF Lauritzsen, et al. 2009 Dose-dense induction followed by autologous stem cell transplant (ASCT) leads to sustained remissions in a large fraction of patients with previously untreated peripheral T-cell lymphomas (PTCLs)-overall and subtype-specific results of a phase II study from Nordic Lymphoma Group Haematologica 94 supplement 2 437 These are preliminary results of large phase II prospective study of ASCT in untreated PTCLs
43. T Relander GF Lauritzsen E Jantunen, et al. 2010 Favorable outcome in ALK-negative anaplastic large-cell lymphoma following intensive induction chemotherapy and Autologous Stem Cell Transplantation (ASCT): a prospective study by the Nordic Lymphoma Group (NLG-T-01) Blood (ASH Annual Meeting Abstracts) 116 21 3566
44. P Reimer 2010 Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphomas Adv Hematol 2010 320624 10.1155/2010/320624 21253465
45. S Le Gouill N Milpied A Buzyn, et al. 2008 Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire J Clin Oncol 26 14 2264 71 18390969 10.1200/JCO.2007.14.1366 This is the largest study evaluating the outcome of PTCL patients treated with allogeneic transplantation
46. ED Jacobsen HT Kim VT Ho, et al. 2011 A large single-center experience with allogeneic stem-cell transplantation for peripheral T-cell non-Hodgkin lymphoma and advanced mycosis fungoides/Sezary syndrome Ann Oncol 22 7 1608 13 21252059 10.1093/annonc/mdq698 1:STN:280:DC%2BC3Mnjt1eitQ%3D%3D
47. OA O'Connor S Horwitz P Hamlin, et al. 2009 Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies J Clin Oncol 27 26 4357 64 19652067 10.1200/JCO.2008.20.8470
48. OA O'Connor B Pro L Pinter-Brown, et al. 2011 Pralatrexate in patients with relapsed or refractory peripheral t-cell lymphoma: results from the pivotal PROPEL study J Clin Oncol 29 9 1182 9 21245435 10.1200/JCO.2010.29.9024 This is the first study evaluating a novel agent specifically in relapsed/refractory PTCL
49. RL Piekarz R Frye HM Prince, et al. 2011 Phase II trial of romidepsin in patients with peripheral T-cell lymphoma Blood 117 22 5827 34 21355097 10.1182/blood-2010-10-312603 1:CAS:528:DC%2BC3MXnsl2nur4%3D This phase II study evaluates romidepsin in relapsed/refractory PTCL
50. B Coiffier B Pro HM Prince, et al. 2010 Final results from a pivotal, multicenter, international, open-label, phase 2 study of romidepsin in progressive or relapsed Peripheral T-Cell Lymphoma (PTCL) following prior systemic therapy Blood (ASH Annual Meeting Abstracts) 116 21 114
51. B Pohlman R Advani M Duvic, et al. 2009 Final results of a phase II trial of belinostat (PXD101) in patients with recurrent or refractory peripheral or cutaneous T-cell lymphoma Blood (ASH Annual Meeting Abstracts) 114 22 920
52. A Forero-Torres S Bernstein A Gopal, et al. 2004 SGN-30 (anti-CD30 monoclonal antibody) is active and well tolerated in patients with refractory or recurrent systemic anaplastic large cell lymphoma Blood 104 11 2637
53. A Shustov R Advani P Brice, et al. 2011 Durable remissions with SGN-et (brentuximab vedotin): updated results of a phase 2 study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) Ann Oncol 22 Supp 4 5 282 This phase II study evaluated brentuximab vedotin in relapsed/refractory ALCL
54. AM Evens LI Gordon D Patton, et al. 2008 Phase I results of combination gemcitabine and bortezomib (Velcade(R)) for relapsed/refractory nodal T-cell Non-Hodgkin Lymphoma (T-NHL) and Aggressive B-Cell NHL (B-NHL) Blood (ASH Annual Meeting Abstracts) 112 11 2005
55. OA O'Connor 2010 Novel agents in development for peripheral T-cell lymphoma Semin Hematol 47 Suppl 1 S11 4 20359580 10.1053/j.seminhematol.2010.01. 014
56. SJ Kim H-S Eom JS Kim, et al. 2010 The efficacy of Bortezomib-CHOP in patients with advanced stage T or NK/T cell lymphomas: the results of multicenter phase II study [abstract] ASH Annu Meet Abstracts 116 21 1791
57. A Delmer P Fitoussi P Gaulard, et al. 2009 A phase II study of bortezomib in combination with intensified CHOP-like regimen (ACVBP) in patients with previously untreated T-cell lymphoma: Results of the GELA LNH05-1 T trial J Clin Oncol 27 15S 8554a
58. G Dueck N Chua A Prasad, et al. 2010 Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma Cancer 116 19 4541 8 20572046 10.1002/cncr.25377 1:CAS:528:DC%2BC3cXht1KnsLrJ
59. PL Zinzani C Pellegrini A Broccoli, et al. 2011 Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified Leuk Lymphoma 52 8 1585 8 21504290 10.3109/10428194.2011.573031 1:CAS:528: DC%2BC3MXovFOqt7s%3D
60. HM O'Leary KJ Savage 2009 Update on the World Health Organization classification of peripheral T-cell lymphomas Curr Hematol Malig Rep 4 4 227 35 20425412 10.1007/s11899-009-0030-5